Stocks Health care TCRT

NASDAQ · Health care

Alaunos Therapeutics, Inc. (TCRT)

Alaunos Therapeutics, Inc. brought in $3K of revenue over the twelve months to June 30, 2026, down 57.1% from a year earlier. It posted a net loss of $4M. In fiscal 2025 capital spending exceeded operating cash flow by $3M. At June 30, 2026 it held $124K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Alaunos Therapeutics, Inc. does

Alaunos Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TCRT.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where TCRT ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Alaunos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 22, 2026
   Material agreement 8-K
2. September 21, 2026
   Securities offering prospectus 424B3
3. September 17, 2026
   Shareholder rights changed 8-K
4. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.41 versus -$0.63.
5. July 6, 2026
   Employee stock plan registration S-8
6. June 29, 2026
   Other event 8-K
7. May 26, 2026
   Other event 8-K
8. May 18, 2026
   Other event 8-K
9. May 15, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.59 versus -$0.67.
10. April 30, 2026
    Annual report (amended) 10-K/A · period to December 31, 2025Revenue fell 50% to $5K versus the prior year; diluted EPS -$2.20 versus -$2.92.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 11, 2026. Insider transactions on SEC

Insider trades

What the people running Alaunos Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 6 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TCRT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 155,493 shares in total.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TCRT

What does Alaunos Therapeutics, Inc. do?

Alaunos Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TCRT.

Is Alaunos Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $4M on revenue of $3K.

How much revenue does Alaunos Therapeutics, Inc. make?

Over the twelve months to June 30, 2026 Alaunos Therapeutics, Inc. reported revenue of $3K. That is 57.1% less than a year earlier.

When did Alaunos Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 22, 2026.

Similar companies

Compare TCRT with

Compare TCRT with any company

Follow TCRT

Get an email when Alaunos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TCRT: get an email when it files

Where the numbers come from

Financial figures are the values Alaunos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.